INOVIO Announces Equity Grant for New Employee Under Inducement Plan

INOVIO Pharmaceuticals Issues Equity Grant to New Hire

INOVIO Pharmaceuticals, a prominent player in biotechnology focusing on DNA-based medicines aimed at treating HPV-related diseases and cancers, recently announced an equity grant under its 2022 Inducement Plan. This targeted initiative is designed to attract and retain top talent in the competitive biopharmaceutical sector.

Details of the Grant

On October 2, 2025, INOVIO reported that its Board of Directors’ Compensation Committee approved an option to grant 1,302 shares of common stock to a recently onboarded employee. This grant, dated September 30, 2025, complies with the Nasdaq Listing Rule 5635(c)(4), which mandates disclosure concerning such inducement awards.

The stock option, priced at $2.34 per share—reflecting the closing price of INOVIO’s shares on the grant date—will vest over a period of three years. Specifically, one-third of the shares are set to vest on each of the first three anniversaries of the grant date, contingent upon the employee’s ongoing employment with the company at those times.

Significance of the Inducement Plan

The Inducement Plan established by INOVIO serves as a strategic approach to not only attract new employees but also to align their interests with long-term company performance. In the ever-evolving field of biotechnology, having skilled professionals who are committed to the company’s goals is critical for success. This grant exemplifies INOVIO's dedication to fostering a workforce that is incentivized to innovate and make significant strides in medical advancements.

About INOVIO Pharmaceuticals

INOVIO Pharmaceuticals stands at the forefront of biotechnology, leveraging its proprietary technology to develop and commercialize innovative DNA medicines. These medicines instruct the body to produce its own disease-fighting tools, a method that has shown promise in protecting against various diseases, including HPV-related conditions and certain cancers. This paradigm shift in treatment not only brings hope to patients afflicted with these diseases but also positions INOVIO as a leader in the rapidly advancing realm of genetic medicine.

INOVIO’s commitment to research and development continues to pave the way for groundbreaking therapies, making it an influential entity within the pharmaceutical industry. The company invites interested individuals to explore more about its initiatives and research by visiting its website at www.inovio.com.

For additional inquiries, media representatives can contact Jennie Willson at 267-429-8567 or via email, while investors can reach out to Peter Vozzo at ICR Healthcare, 443-213-0505 for investor relations.

As INOVIO moves forward, the industry watches closely, anticipating the future advancements that will emerge from their innovative spirit and scientific expertise.